ING116070: a study of the pharmacokinetics and antiviral activity of Dolutegravir in cerebrospinal fluid in HIV-1–infected, antiretroviral therapy–naive subjects
SL Letendre, AM Mills, KT Tashima… - Clinical Infectious …, 2014 - academic.oup.com
SL Letendre, AM Mills, KT Tashima, DA Thomas, SS Min, S Chen, IH Song, SC Piscitelli
Clinical Infectious Diseases, 2014•academic.oup.comMedian dolutegravir concentrations in cerebrospinal fluid were similar to unbound
concentrations in plasma and all subjects exceeded the in vitro 50% inhibitory concentration
for wild-type viruses (0.2 ng/mL) by≥ 66-fold, suggesting therapeutic concentrations are
achieved in cerebrospinal fluid..
concentrations in plasma and all subjects exceeded the in vitro 50% inhibitory concentration
for wild-type viruses (0.2 ng/mL) by≥ 66-fold, suggesting therapeutic concentrations are
achieved in cerebrospinal fluid..
Median dolutegravir concentrations in cerebrospinal fluid were similar to unbound concentrations in plasma and all subjects exceeded the in vitro 50% inhibitory concentration for wild-type viruses (0.2 ng/mL) by ≥66-fold, suggesting therapeutic concentrations are achieved in cerebrospinal fluid..
Oxford University Press